Small-cap health care company Nevro tumked -14.2% this afternoon, reaching $23.62 per share. In contrast, the average analyst target price for the stock is $39.67.
Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company is based in the United States.
What to Consider if You Are Thinking of Buying Nevro:
-
Nevro has moved -43.7% over the last year.
-
NVRO has a forward P/E ratio of -13.9 based on its EPS guidance of -1.7.
-
Over the last 4 years, earnings per share (EPS) have been growing at a compounded average rate of 0.6%.
-
The company has a price to earnings growth (PEG) ratio of -0.45.
-
Its Price to Book (P/B) ratio is 2.8
Nevro Has Irregular and Negative Cash Flows
| Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cashflow ($ k) | YoY Growth (%) |
|---|---|---|---|---|
| 2022-12-31 | 24,675 | -7,542 | 17,133 | 131.6 |
| 2021-12-31 | -41,881 | -12,340 | -54,221 | -1021.66 |
| 2020-12-31 | 1,191 | -6,025 | -4,834 | 91.0 |
| 2019-12-31 | -50,225 | -3,472 | -53,697 | n/a |
Nevro has negative and highly variable free cash flows. They've averaged $-23.9 Million over the last 4 years, during which time they grew at a 7.2% compounded rate while displaying a coefficient of variability of 149.9%.
